Corona Remedies Limited
ListedMainboardHealthcare & Pharmaceuticals · NSE / BSE
Corona Remedies Limited, incorporated in August 2004, is a pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas including women’s healthcare, cardiology, pain management, urology, and multispecialty segments. As of December 2024, its portfolio includes 67 brands covering women’s health, cardio-diabetic care, pain relief, urology, and multispecialty products such as vitamins, minerals, nutrition, gastrointestinal, and respiratory medications. The company has established a strong pan-India presence with 2,598 medical representatives across 22 states, ensuring deep engagement with healthcare professionals and hospitals. It operates two manufacturing facilities in Gujarat, supporting its production and quality-focused growth strategy in the Indian Pharmaceutical Market.
Price Band
₹1008 – ₹1062
Issue Size
₹655 Cr
Lot Size
14 shares
GMP
₹344
+32.4%
Est. Listing
₹1406
at current GMP
Subscribed
144.49x
overall
Open
8 Dec 2025
Close
10 Dec 2025
Allotment
11 Dec 2025
Refund
12 Dec 2025
Demat Credit
13 Dec 2025
Listing
15 Dec 2025
Last updated 12 days ago
Overall Subscription
144.49x
Total Demand
QIB Multiplier
293.80x
Institutions & Funds
NII / HNI
220.18x
High Net-Worth
Retail (RII)
30.29x
Individual Bidders
Category-Wise Subscription Breakup
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 1,221,729 | 358,939,448 | 293.80x |
| NIB | 916,960 | 201,897,066 | 220.18x |
| HNIs(10L +) | 611,307 | 150,793,356 | 246.67x |
| HNIs (2-10L) | 305,653 | 51,103,710 | 167.20x |
| RETAIL | 2,139,573 | 64,802,052 | 30.29x |
| EMPLOYEES | 58,036 | 902,888 | 15.56x |
| Total | 5,253,258 | 828,438,520 | 144.49x |
Application-Wise Breakup
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| RETAIL | 152,827 | 3,792,248 | 24.81x |
| EMPLOYEES | — | 35,988 | 0.00x |
| HNIs(10L +) | 3,119 | 155,224 | 49.77x |
| HNIs (2-10L) | 1,559 | 249,992 | 160.35x |
| Total Applications | 157,505 | 4,233,452 | 26.88x |
Day-Wise Subscription Progress
Track continuous institutional and retail bidding order books for all active issues on the ipo live subscription feed.
About Corona Remedies Limited Public Issue & Market Profile
Corona Remedies Limited is bringing an initial public offering (IPO) in the Healthcare & Pharmaceuticals sector with an aggregate issue size of ₹655.37 Crores. The shares are offered at a price band of ₹1008 to ₹1062 per equity share on NSE and BSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Bidding & Quota Instructions:
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 14 shares (approx. ₹14,868 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment Reconciliation Schedule:
Allotment reconciliation will be managed by Bigshare Services Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2025-12-13, while un-allotted funds or UPI block mandates will be released on 2025-12-12.
Frequently Asked Questions
What is Corona Remedies Limited IPO GMP today?
The latest Grey Market Premium (GMP) for Corona Remedies Limited IPO is ₹344 per equity share. Based on the upper price band of ₹1008 to ₹1062 per equity share, the estimated listing price is ₹1406 (+32.4% expected listing gain).
What is the expected profit per lot for Corona Remedies Limited IPO?
With a lot size of 14 shares and current GMP of ₹344, the expected profit per application lot is approx ₹4,816 (+32.4% gain). Minimum application cost is approx ₹14,868.
What is the issue size and price band for Corona Remedies Limited IPO?
The Corona Remedies Limited IPO aggregate issue size is ₹655.37 Crores with an equity price band set at ₹1008 to ₹1062 per equity share. The retail lot size is 14 shares requiring a minimum capital outlay of approx. ₹14,868.
How can I check Corona Remedies Limited IPO live subscription demand?
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. Currently, overall subscription is 144.49x (Retail: 30.29x, QIB: 293.80x, NII: 220.18x). You can track live multiples directly on our dedicated subscription page.
Where and when will Corona Remedies Limited IPO allotment status be published?
The basis of allotment will be published on the official registrar portal (Bigshare Services Private Limited) and the BSE status verification website on or around 2025-12-11. Investors can verify status using PAN card or application number.
When is the listing date for Corona Remedies Limited IPO?
Corona Remedies Limited shares are scheduled to list on NSE and BSE on 2025-12-15.